Please login to the form below

War on drugs: the use of controlled substances in medicine

Infamously coined America’s ‘public enemy number one’ by President Nixon, are controlled substances a fundamental missing part of modern medicine? By Emma Gorton, Senior Director at Hanover Communications

On 17 June 1971, President Nixon declared drug abuse as America’s ‘public enemy number one’ and launched what has since become known as the ‘war on drugs'.

Controlled substances were from thereon positioned as a common enemy to unite people, and many argue that President Nixon used the war on drugs as a political tool to criminalise certain groups who were viewed as enemies of the Nixon administration.

Nixon’s war on drugs meant that all research into controlled substances’ efficacy on health conditions was halted. These substances were deemed the enemy and that was that.

Now, fifty years later in 2020, we are seeing a rise in the number of clinical trials investigating controlled substances for the treatment of medical conditions; medical conditions such as mental disorders which are now among the leading causes of ill-health and disability worldwide.

Psilocybin (aka magic mushrooms) has shown promise in treating a variety of difficult-to-treat health conditions such as depression and cancer-related anxiety. Ketamine has shown efficacy in the treatment of mental health conditions with the FDA approving a version of it, esketamine nasal spray, in March 2019 for treatment-resistant depression. Earlier this year, the FDA granted application for an Expanded Access Program for MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder. And not forgetting cannabis, a drug which is booming and infiltrating all areas of health and wellness including skincare and beauty treatments. It has shown promise in mental health conditions, skin conditions and a cannabis-based medicine is now available on the NHS for the treatment of epilepsy.

This shouldn’t come as a surprise to us as in our earliest days as a species, we used controlled substances in a medicinal way. In shamanism, for example, psychedelics would be commonly administered for those with severe medical or psychological problems as part of healing ceremonies.

So why are we in the western world in 2020, only just kickstarting our research into these breakthrough substances now?

Nixon’s war on drugs certainly plays a role and has had a significant detrimental impact on the advancement of treatment for mental health conditions. If Nixon hadn’t launched his war on drugs back in the 70s, we would have an extra fifty years of research into controlled substances behind us and mental health conditions may  be better managed and treated. It is frightening how little we actually know about the brain and the war on drugs has contributed to this lack of progress.

Looking to the future, the rise of clinical trials in controlled substances is something to be optimistic about, however, bringing these medicines to market will have challenges. Most significantly, there are fifty years’ worth of bad reputation to contend with, so ultimately even if these substances are found to be efficacious there will be a huge need to change public perception and to ensure the correct policy is in place so patients can access the treatments. Our speciality of mix of communications, policy and market access at Hanover is designed to do just that.

15th April 2020

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

What's next for the 'indispensable' health system?
No one is remotely indispensable” – those of the words many of us have heard these past few weeks. As Boris Johnson and the previously incumbent Cabinet are now considering their next moves, where does that leave health policy at one of the most volatile points in recent history? We were set for a bumper few months of hotly anticipated announcements, including the 10-Year Cancer  Plan response, the Women’s Health Strategy, and the implementation plan for the Life Sciences Vision, amongst many others. But what will happen as the forthcoming leadership contest dominates the column inches? How will the Civil Service and NHS stand up to the challenges it faces without certainty of who is steering the ship? We will explore some of the possibilities of what will happen next, and most importantly, how we in communications can support the health system at such a critical time post-pandemic. To find out, read the latest blog on the PM Hub, penned by Hanover Health's Senior Account Director Ursula Ritz.
Hanover Communications
How can the UK be a catalyst for change in women’s health? 
Women’s health has once again been thrust to the fore, with almost daily stories on hormone replacement therapy (HRT) supply shortages in the UK providing us with a stark reminder of the challenges women are facing in this country every day. The good news is, the UK Government is making a genuine and concerted effort to tackle women’s health issues, having set out its Vision for women’s health in December, and a full Strategy due to be published imminently. We have a real opportunity to change women’s experience of healthcare for the better, but we cannot afford to get this wrong. In her latest blog, Hanover’s Georgia Hunt explores how the upcoming Women’s Health Strategy should address the concerns of women today and improve the lives of the women of tomorrow.
Hanover Communications
Innovative contracting at the top of the market access agenda
Value-based contracting (VBC) is firmly on the market access agenda across Europe and there are converging views on what is needed in this space.  Pharma and biotech, patients, payers, regulators and HTA agencies gathered at the World Evidence, Pricing and Access Congress in March to discuss challenges and potential solutions. Hanover hosted a discussion about experiences of VBC and where changes are needed. We explored whether a global archetype approach could support in-country negotiating agreements.   In their latest blog, Hanover Health’s Emma Eatwell and Josie Godfrey explore what the future for VBC might look like.
Hanover Communications
The future of nanomedicine regulation
With the EU’s upcoming revision of the general pharmaceutical legislation, the bloc has the chance to provide long-awaited clarity around the future of nanomedicine. And just as important, it will give the EU a chance to lead on a conversation around the needed regulatory framework for nanomedicines as other countries -including the US- currently struggle with this. In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 vaccines is more important than ever.
Hanover Communications
Getting it Right First Time: Building a Value-Based Contract Strategy
In their latest blog, Hanover Brussels Emma Eatwell and Josie Godfrey will explore how companies can efficiently and effectively increase the chances of securing value-based contracts that work for all.
Hanover Communications
The role of pharma in breaking through the backlog
As health systems emerge from the pandemic, and attention turns to the backlog of patients waiting for treatment, how can the pharmaceutical industry position itself as part of the solution? In his latest blog, Hanover Health’s Alexander Davies looks to answer the following questions – big pharma was there for the world when it needed vaccines in record-breaking time, can it find the innovations that we need now to clear through the queue of people waiting for treatment? Can it partner with health systems to speed up access, improve patient outcomes and reduce the burden on healthcare professionals? And, if it did so, what are the opportunities for its reputation?
Hanover Communications